Skip to main content
Erschienen in: Reactions Weekly 1/2021

01.07.2021 | Case report

Azathioprine/infliximab/mesalazine

Lack of efficacy: case report

Erschienen in: Reactions Weekly | Ausgabe 1/2021

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Dalal RS, et al. Two Strikes but Not Out: Deep Remission of Ulcerative Colitis with Ustekinumab After Primary Non-response to Infliximab and Vedolizumab. Digestive Diseases and Sciences 66: 733-737, No. 3, Mar 2021. Available from: URL: http://doi.org/10.1007/s10620-021-06852-3 Dalal RS, et al. Two Strikes but Not Out: Deep Remission of Ulcerative Colitis with Ustekinumab After Primary Non-response to Infliximab and Vedolizumab. Digestive Diseases and Sciences 66: 733-737, No. 3, Mar 2021. Available from: URL: http://​doi.​org/​10.​1007/​s10620-021-06852-3
Metadaten
Titel
Azathioprine/infliximab/mesalazine
Lack of efficacy: case report
Publikationsdatum
01.07.2021
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2021
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-021-98994-0

Weitere Artikel der Ausgabe 1/2021

Reactions Weekly 1/2021 Zur Ausgabe

Case report

Metronidazole

Case report

Oxytocin

Case report

Multiple drugs

Case report

Hyaluronic acid